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OBJECTIVES: Infliximab is indicated in Crohn’s disease (CD) resistant to standard
treatment (ST), but its impact on health care costs and quality-adjusted life-expec-
tancy is incompletely understood. We assessed the cost-effectiveness of episodic
(ET) and maintenance (MT) infliximab treatment in CD patients with 10-years
follow-up. METHODS: A total of 212 incident adult CD patients (age at onset
34.414.5 years, 49.4% male) were treated with antibiotics, mesalazine, corticoste-
roids, thiopurines, surgery (comprising ST) over 10-years to 2004. Eight health
states were defined by intensity of therapy in these patients. We determined
Markov transition probabilities between these states, health care costs and QALYs
in 3 month-cycles. This cohort was modeled to allow drug-refractory or pre-surgery
patients to receive infliximab: either ET in one cycle, or MT in responders for a
period of 1-year (MT-1yr) or for 10-years (MT-10 yrs). Transition probabilities of ST
were applied to patients getting IFX; the probability of continuing infliximab in MT
was set to correct for decay. Health care costs and QALYs in ET and MT were
estimated for 10-years (discounted at 3%) and compared with those of ST patients.
RESULTS: The average cost (QALYs gained) per patient over 10-years was €23,169
(6.7014) for ST; €21,691 (7.0403) for ET, €29,012 (7.0553) for MT-1yr, and €50,416
(7.2603) for MT-10 yrs. ST was associated with higher costs and lower outcomes and
was thus dominated by ET. The incremental cost-effectiveness ratios (ICERs) of
MT-1yr and MT-10 yrs over ST were €16,510/QALY gained, and €48,751/QALY
gained, respectively. When compared with ET, the ICERs of MT-1yr and MT-10 yrs
were €488,066/QALY gained, and €130,568/QALY gained, respectively. When the
infliximab price was halved these ICERs remained very high. CONCLUSIONS: ET or
MT with infliximab are either cost-saving or cost-effective when compared with
ST. However, at current drug prices, MT does not provide good value for money
when compared with ET.
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OBJECTIVES: To evaluate direct medical costs, health outcomes, and cost-effec-
tiveness of 48-week Peginterferon alpha-2a with 2nd line 2-years Entecavir
treatment versus 3 years Entecavir treatment for HBeAg-positive chronic hep-
atitis B according to the Response Guided Treatment (RGT) strategy in China.
METHODS: A Markov model was designed to evaluate the direct medical costs
and outcomes (life years and QALYs gained) of treating HBeAg-positive chronic
hepatitis B in China, with a maximum analysis time horizon of 80 years. The
model included 10 health states – Chronic hepatitis B (CHB), HBeAg seroconver-
sion, HBsAg loss, CHB with resistance, Compensated cirrhosis, Decompensated
cirrhosis, Hepatocellular carcinoma, Liver transplant, Post-liver transplant and
death. Based on the analysis of published literature, a two-round expert panel
survey was conducted among 22 hepatitis B specialists nationally to identify
clinical and utility data. From the perspective of China’s health insurance sys-
tem, cost data was calculated based on the published literature about CHB
economic burden. A discounting rate at 3% was used to discount medical costs
and health outcomes that happened at different years. A univariate sensitivity
analysis was performed to understand the key drivers and general sensitivity of
the model. RESULTS: The model results showed that the utilization of Peginter-
feron regimen can prolong1.80 QALYs (15.00 years vs. 13.20 years), compared to
the 3 years Entecavir treatment. The total cost per patient treated with Pegin-
terferon and Entecavir was RMB 163,638 yuan (US$ 25,568) and RMB 145,116
yuan (US$ 22,674), respectively. The discounted incremental cost per QALY
gained for Peginterferon regimen was RMB 10,298 yuan (US$ 1,609) (Exchange
rate: 1 US$  6.4 CNY). CONCLUSIONS: The results of the model suggest that
48-week Peginterferon alpha-2a with 2-years Entecavir treatment as 2nd line
improves health outcomes in a cost-effective manner compared with 3 years
Entecavir for the treatment of HBeAg-positive chronic hepatitis B in China.
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OBJECTIVES: To estimate the cost-effectiveness of telaprevir in combination
with peginterferon alpha and ribavirin (PR) compared to PR alone in previously
treated patients. METHODS: A cost-utility analysis based on previously pub-
lished Markov models for chronic hepatitis C was used. Efficacy in the model
was derived from results of randomized placebo controlled trial (REALIZE). RE-
ALIZE compared telaprevir in combination with PR to PR alone in patients who
failed previous treatment. The trial showed significantly higher response rates
in the telaprevir patient cohort. Utility values corresponding to each health
state in the model were obtained from a NICE Health technology Assessment
and were combined with data from REALIZE. Local cost data sources were from
published price lists, clinical guidelines, product labels and expert opinion (DEL-
PHI panel). The effectiveness was measured in quality-adjusted life years
(QALY). Time horizon was set at lifelong (100 years of age or till patient dies) and
a payers’ perspective was adopted. Discount rate was 5% per year for both costs
and effects according to actual Ministry of Health guidelines for health eco-
nomic evaluation. Both one-way and probabilistic sensitivity analyses were
performed. RESULTS: Incremental cost effectiveness ratio (ICER) for telaprevir
in combination with PR compared to PR alone was 14 209 €/1 QALY. Costs for one
life year saved (LYS) were 20 026 €/1 LYS. Model was most sensitive to price of
telaprevir in deterministic sensitivity analysis. In probabilistic sensitivity anal-
ysis 75 % of simulations were below 26 650 €/1 QALY. CONCLUSIONS: Telaprevir
in combination with PR is a cost-effective compared to PR alone for the treat-
ment of chronic hepatitis C in patient who failed previous treatment with PR in
a Slovakian health care system.
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OBJECTIVES: Linaclotide is a novel once daily, orally delivered peptide that acts on
all key IBS-C symptoms. The aim of this analysis was to estimate the daily cost that
would result in linaclotide being considered cost-effective in the UK, given differ-
ent levels of willingness–to-pay (WTP).METHODS:A within-trial analysis was used
to estimate the economically justifiable price from a payer perspective in the UK
using patient-level data from a 26-week Phase III, randomized, double-blind trial of
linaclotide 290g daily (n401) versus placebo (n403) in IBS-C patients (modified
Rome II criteria). EQ-5D data was collected at randomization and each subsequent
visit. The UK valuation of the EQ-5D was applied to the raw data to estimate the
utility for each patient. Missing data were interpolated using the last-observation-
carried-forward (LOCF) method. The WTP was varied from £15,000-£20,000/QALY.
The only cost considered was that of linaclotide; total cost of treatment was
weighted by compliance. Resource use was assumed to be equal between arms.
Bootstrapping was performed to account for uncertainty. A scenario analysis was
conducted using data from a 12-week linaclotide trial in a similar population.
RESULTS: Patients treated with linaclotide gained 0.016 QALYs over the 26-week
trial compared with patients in the placebo arm. At WTP thresholds of £15,000-
£20,000/QALY linaclotide could be cost-effective at a price of £1.30-£1.70. Over 75%
of the bootstrap estimates fell below a willingness-to-pay threshold of £20,000/
QALY. The method of addressing missing data had minimal impact on the ICER. In
the scenario analysis, the QALY gain for patients treated with linaclotide was even
greater, thus a price of £2.00-£2.65 may result in linaclotide being considered cost-
effective at thresholds of £15,000-£20,000/QALY. CONCLUSIONS: The base case
analysis showed linaclotide could be cost-effective at a price of up to £1.70/day in
the UK setting using conservative assumptions.
PGI27
IMPACT OF LINACLOTIDE TREATMENT ON WORK PRODUCTIVITY AND
ACTIVITY IMPAIRMENT IN ADULTS WITH IRRITABLE BOWEL SYNDROME WITH
CONSTIPATION
Buono JL1, Tourkodimitris S1, Sarocco P2, Baird MJ2, Johnston JM2, Carson R1
1Forest Research Institute, Jersey City, NJ, USA, 2Ironwood Pharmaceuticals, Cambridge, MA,
USA
OBJECTIVES: Irritable bowel syndrome with constipation (IBS-C) can decrease
work productivity and increase activity impairment, resulting in a substantial
economic burden for patients and employers. Linaclotide, a minimally-ab-
sorbed guanylate cyclase C agonist (GCCA), significantly improved abdominal
and bowel symptoms in 2 Phase 3 IBS-C trials. We evaluated the linaclotide
treatment effect on work productivity and activity impairment in IBS-C
patients. METHODS: In 2 Phase 3 trials, 1602 adults with IBS-C (modified Rome II
criteria) were randomized to oral linaclotide 290 g once daily or placebo. The
self-administered 6-item Work Productivity and Activity Impairment question-
naire for IBS-C (WPAI:IBS-C) was used to evaluate IBS-C symptom-related ab-
senteeism (work hours missed), presenteeism (degree symptoms affected work
productivity), overall work productivity loss (absenteeismpresenteeism) and
daily activity impairment (degree symptoms affected activities) over the previ-
ous week. Using pooled intent-to-treat data, changes in WPAI:IBS-C scores from
baseline to Weeks 4, 8, and 12 were assessed by analysis of covariance and
represented as percentages (higher percentagegreater productivity loss and
activity impairment). Absenteeism, presenteeism and work productivity as-
sessments included employed patients only. RESULTS: Compared to placebo,
linaclotide significantly reduced presenteeism, overall work productivity loss
and daily activity impairment, and numerically decreased absenteeism, at
Weeks 4, 8 and 12. Mean changes from baseline to Week-12 for linaclotide and
placebo, and the corresponding treatment effect (LS-means difference between
linaclotide and placebo, shown as “	”), respectively, were: presenteeism, -18.4%
and -13.1% (	-5.2, P0.0001); overall work productivity loss, -19.4% and -13.0%
(	-6.1, P0.0001); daily activity impairment, -19.9% and -15.2%(	-4.7,
P0.0001); absenteeism, -1.6% and -0.9% (	-0.5, P0.311). Assuming a 40-hour
work week, linaclotide reduced overall work productivity loss by 1.6-2.4
hours/week. CONCLUSIONS: Linaclotide significantly reduced presenteeism,
overall work productivity loss and daily activity impairment for IBS-C patients
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versus placebo. Significant improvements were evident at Week-4 and main-
tained through Week-12.
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OBJECTIVES: Few studies have evaluated the impact of GERD-symptoms on
work productivity and no French data are available. The aim of this study was to
evaluate the impact of GERD typical symptoms on work productivity and daily
activities in patients with nocturnal compared to diurnal symptoms. METHODS:
A prospective, multicenter, observational study was carried out in French pri-
mary care setting. Each physician had to include the first two consecutive adult
patients on full-time job who had experienced GERD typical symptoms at least
once during the 7 days/nights preceding the inclusion visit: 1 with exclusively
diurnal symptoms and 1 with nocturnal symptoms. Data collected by physi-
cians were: patients’ characteristics, symptomatology and treatments. Work
productivity loss was assessed using the validated self-administered Work Pro-
ductivity and Activity Impairment questionnaire specific to GERD (WPAI-GERD).
Predictors of work productivity loss were identified by multivariate regression
models and its cost estimated. RESULTS: A total of 407 physicians included 716
eligible patients: 50.8% with nocturnal and 49.2% with exclusive diurnal symp-
toms (EDS). The mean age was 46.3 years (SD 8.7), 62.8% were men, and 58.3% of
patients diagnosed before inclusion were treated for GERD. Work productivity
and daily activities decreased by 31.4% and 32.6%, respectively. Decrease rates
were higher in EDS-patients (p0.001 each). Work productivity impairment was
mostly due to impairment while working (presenteeism) rather than absentee-
ism. The symptoms intensity and composite intensity index, reflecting disease
severity, were identified as the main predictors of decreased work productivity.
The mean cost of work productivity loss per patient was estimated as €313/
week, also higher in EDS-patients (p0.001). CONCLUSIONS: GERD incurs high
work productivity loss which yields a substantial burden. Improving patients’
outcomes, especially in those with moderate or severe disease, with most ef-
fective tailored treatments and care management could be expected to reduce
work productivity loss and associated costs.
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OBJECTIVES: To assess average direct medical costs of treatment of consecutive
stages of HCV in Poland. METHODS: A questionnaire study in 7 medical centres
among experienced clinicians (1200 patients managed annually in total) was per-
formed. Six separate questionnaires were prepared and initially validated for de-
fined HCV health states: mild hepatitis-MiH, moderate hepatitis-MoH, compen-
sated cirrhosis-CoC, decompensated cirrhosis-DeC, hepatocellular carcinoma-
HCC and post liver transplant phase–1st (PLT1) and 2nd(PLT2) year of follow-up.
Each professional was asked for describing a typical procedures set conducted in
an theoretical average patient in specified chronic hepatitis C health state. The
procedures sets consisted of a few main categories: hospitalisation, ambulatory
care, diagnostic procedures, pharmacotherapy, rehabilitation, adequately to dis-
ease phase and in accordance with official procedures lists published by National
Health Fund for 2011. Antiviral treatment was excluded from the analysis.
RESULTS: Five questionnaires for each of mild hepatitis, moderate hepatitis, com-
pensated cirrhosis, decompensated cirrhosis, and two for HCC and post liver trans-
plant health states, were obtained. Calculated mean annual costs of defined health
states and their relation to the cost of liver transplantation in Poland (200000PLN
48000€ in 2010) are as follow: MiH with SVR–422PLN (99€), 0,2%; MoH with SVR–
800PLN (188€), 0,4%; CoC with SVR–2018PLN (475€), 1,0%; MiH no SVR–2384PLN
(561€), 1,2%; MoH no SVR–3097PLN (729€), 1,5%; CoC no SVR–4995PLN (1175 €), 2,4%;
DeC–14860PLN (3496€), 7,3%; HCC–38927PLN (9159€), 19,0%; PLT1–30626PLN (7206€),
15,0%; PLT2–19973PLN (4699€), 9,8%. CONCLUSIONS: There is a marked increase of
mean annual costs of standard treatment of HCV patients along with disease stage.
Assuming that in Poland about 700000 individuals can be infected with HCV, most
of them being unaware of the disease, high costs of complications of chronic hep-
atitis-C are serious social and economic burden. National screening programme
with effective antiviral treatment at early stages of disease can reduce this negative
impact on society.
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OBJECTIVES: To understand resource utilization and costs associated with refer-
rals and testing for patients with irritable bowel syndrome with constipation
(IBS-C) based on treatment response. METHODS: A web-based survey was con-
ducted for a sample of primary care physicians (PCPs) and gastroenterologists (GEs)
across different US regions. The survey captured data on referral patterns (to/from
gastroenterologists), test/procedure ordering, and follow-up physician visits for
typical patients who did and did not achieve a satisfactory relief of symptoms to a
recent treatment for IBS-C (“response”). Survey items included questions regarding
the proportion of patients who would receive tests/procedures and follow-up phy-
sician visits. Health care costs were estimated by applying associated unit costs
(derived from the 2012 Medicare physician payment schedule) to the correspond-
ing utilization. All patients were assumed to begin treatment with PCPs. The cost of
treatment failure was defined as the cost difference between physician-deemed
non-responders and responders, incorporating both PCP work-up costs and the
costs of referrals to GEs. RESULTS: Twenty PCPs and 21 GEs completed the survey.
Mean monthly number of adults treated by the physicians was 61. Most non-re-
sponders (median: 80%; mean: 72%) would be referred to a GE by PCPs. Non-re-
sponders would be more likely to receive a test/procedure compared to responders
(median: 75 vs. 0% for PCPs; 50 vs. 0% for GEs; mean: 65 vs. 10% for PCPs; 56 vs. 33%
for GEs). Thyroid function tests, complete blood count, and colonoscopy were the
most common tests/procedures that would be ordered, by both PCPs and GEs. The
median (mean) expected cost of treatment failure was estimated to be $825 ($613).
CONCLUSIONS: Not responding to treatment may result in referral to a specialist
and/or additional testing and procedures, which may lead to higher health care
resource use and costs among patients with IBS-C, a finding of potential interest to
payers.
GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: To assess the impact of treatment response on quality of life (QOL)
and work productivity for patients with irritable bowel syndrome with constipation
(IBS-C). METHODS: Irritable Bowel Syndrome - QOL (IBS-QOL) score, EQ-5D index
score, work productivity, and IBS symptom relief were collected in two phase III
randomized placebo-controlled clinical trials of linaclotide, an investigational
treatment for IBS-C. Treatment response for IBS-C was defined as (1) a  14-point
increase at Week 12 from baseline on the overall IBS-QOL score or (2) moderately or
significantly relieved on a seven-point Likert scale on global symptom relief for 2
out of 3 months. Hours of work missed due to IBS-C were collected using the Work
Productivity and Activity Impairment (WPAI) Questionnaire. Data from the intent-
to-treat populations were pooled for linaclotide and placebo across two trials.
EQ-5D index score and work productivity were evaluated among responders and
non-responders. RESULTS: Patients were analyzed with available EQ-5D and IBS-
QOL data (n1,487) and available EQ-5D and IBS symptom relief data (n1,558),
with response rates of 46% and 14% respectively. Patients were analyzed with
available WPAI and IBS-QOL data (n1,056) and WPAI and IBS symptom relief data
(n1,103), with response rates of 47% and 15%, respectively. Responders had sta-
tistically significantly higher EQ-5D scores at Week 12 than non-responders, for
both definitions (IBS-QOL: 0.85 vs. 0.81, IBS symptom relief: 0.91 vs. 0.81, both
P0.05). Responders were statistically significantly less likely to miss 1 hour of
work during 12 weeks for IBS-C (IBS-QOL: 16.0% vs. 21.7%, IBS symptom relief: 9.6%
vs. 20.8%, both P0.05). CONCLUSIONS: Improvements in disease-specific mea-
sures correlate with improvements in health utilities and reduced work absentee-
ism among patients with IBS-C.
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OBJECTIVES:Despite Italy has a large HCV infected pool (1.500.000 estimated) novel
Direct Antiviral Agents (DAAs) against HCV genotype 1 have not yet been approved.
As the estimated budget to cover all eligible patients could be ten-fold higher,
limitations or patient selections could be applied. The study purpose is to obtain
the patients’point of view about associated costs, sustainability, possible scenarios
related to the lack of economic resources. METHODS: EpaC is the most important
Italian NGO for HCV patients. An anonymous web-based questionnaire was pub-
lished on the association website www.epac.it. It was composed of multiple choice
questions and was preceded by a scenario reporting a mean drug cost per patient
per course of 25.000-35.000 €, the availability of interferon-free monotherapy DAAs
drugs in the nearest future, different reimbursement possibilities (payment-by-
results, expenditure thresholds . . .). RESULTS: A total of 763 patients participated
the survey and 727 questionnaires were considered validly compiled. The profile of
the participants was assessed concerning sex, age, geographical provenience,
health condition, fibrosis stage, eligibility for triple treatment. 83% of patients
claimed equity of access independently of disease severity, 55% is not inclined to
postpone the treatment despite 62% of these has low/medium fibrosis, 77% of
participants does not tolerate the lack of resources that could lead to patient se-
lection, 40% is disposed to travel anywhere to get the most appropriate therapy.
CONCLUSIONS: This was a unique and the largest survey on Italian patients about
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